Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Ma
VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TM Platform. LENSai, which is run by the company's subsidiary, BioStrand, provides a unique and co...
Source: pharmiweb.com
